Drug Trial Radar · NCT02633501
P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
Last checked: Nov 20, 2026Latest source record: Oct 25, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
312
Actual
Start
Jun 2016
Primary completion
Jan 2018
Study completion Jan 2018
Sponsor
- Lead sponsor
- GuerbetIndustry
- Sponsor type
- Industry
- First posted
- Dec 17, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to determine a safe and effective dose of a new gadolinium-based contrast agent (GBCA) P03277 based on the Contrast to Noise Ratio (CNR) when comparing with gadobenate dimeglumine (MultiHance®) at 0.1 mmol/kg body weight (BW). Contrast to Noise Ratio (CNR), a well-known quantitative parameter directly related to contrast medium/GBCA efficacy, was chosen as the primary endpoint in order to have a precise determination of P03277 clinical dose. This was a multi-center, international, prospective, double-blind, randomized, controlled, parallel dose groups, cross-over with comparator study in male and female subjects presenting with known or highly suspected focal areas of disruption of the Blood Brain Barrier including at least one expected enhancing lesion of minimum 5 mm, who were scheduled to undergo a routine contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System.
Conditions
- CNS Lesion
- Blood Brain Barrier Defect
Interventions
P03277Drug
Single intravenous (IV) bolus injection at a rate of 2 mL/second
Gadobenate dimeglumineDrug
Single IV bolus injection at a rate of 2 mL/second
MRIDevice
Primary outcomes
What the sponsor says the trial is designed to measure.
- Contrast to Noise Ratio (CNR) DifferenceTime frame: 1 day procedure
Locations
28 sites in 8 countries. Site status is shown where the registry gives one.
Northwestern memorial hospital
Chicago, Illinois
Beth israel deaconess medical center
Boston, Massachusetts
QUEST Research Institute
Farmington Hills, Michigan
Penn State milton S. Hershey Medical center
Hershey, Pennsylvania
University of Pensylvania medical center
Philadelphia, Pennsylvania
Temple university hospital
Philadelphia, Pennsylvania
Rhode Island hospital
Providence, Rhode Island
Medical University of South Carolina
Charleston, South Carolina
University of texas McGovern medical school
Houston, Texas
University of Washington
Seattle, Washington
ZNA campus Middelheim
Antwerp, Belgium
Universitair Ziekenhuis Brussel
Brussels, Belgium
Fakultni nemocnice Olomouc
Olomouc, Czechia
Neurology Clinic-Semmelweis Medical University
Budapest, Hungary
Pecsi Tudomany Egyetem Klinikai kozpont Idegsebeszeti Klinica
Pécs, Hungary
Ospedali Riuniti di Ancona
Ancona, Italy
Ospedale san Raffaele
Milan, Italy
AO S. Andrea Universita La Sapienza
Roma, Italy
Azienda policlinico Umberto
Roma, Italy
Centro medico ABC santa fe
Mexico City, Mexico
Axis heilsa
Monterrey, Mexico
Clinical research institute SC
Tlalnepantla, Mexico
Centrum Onkologii Instytut im. Marii Sklodowskiej-Curie, Oddzial w Gliwicach
Gliwice, Poland
krakowski Szpital specjalistyczny il Jana Pawla II
Krakow, Poland
Samodzielny publiczny szpital
Lublin, Poland
Asan medical center
Seoul, South Korea
Samsung medical center
Seoul, South Korea
Seoul National university hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.